In order to develop translatable gene therapy for CMT1X, we used here an AAV9 vector driven by the Schwann cell-specific Mpz promoter in order to achieve targeted GJB1 gene expression in Schwann cells throughout the PNS. This evidence concerns the gene MPZ and X-linked Charcot-Marie-Tooth disease type 1.